In this issue:
European guideline for melanoma: 2022 treatment update
Melanoma risk during immunomodulating treatment
Relatlimab + nivolumab vs nivolumab in untreated advanced melanoma
Epidemiologic analysis of melanoma overdiagnosis in the USA, 1975-2017
Comparative genomics provides insights into melanoma subtypes
Five-year analysis of adjuvant pembrolizumab in stage III melanoma
Pilot study of patient-led surveillance after treatment of localised melanoma
Review of neoadjuvant systemic therapy in melanoma from INMC
Long-term outcomes with nivolumab + ipilimumab or nivolumab alone vs ipilimumab in patients with advanced melanoma
Please login below to download this issue (PDF)